Abstract 1013TiP
Background
Prompt detection of hepatocellular carcinoma (HCC) in patients with chronic liver diseases is critical for enhancing prognosis. Existing imaging techniques and serum markers fall short of clinical needs. This study aims to establish a non-invasive GAMAD test model for early HCC detection by incorporating demographic data (Gender and Age), circulating tumor DNA (ctDNA) Methylation signature in blood, and commonly utilized serum biomarkers [alpha-fetoprotein (AFP), des-γ-carboxy-prothrombin (DCP)]. Additionally, the study will evaluate the model's effectiveness among HCC patients at various stages and/or high-risk HCC groups.
Trial design
This prospective, multicenter, non-interventional study will enroll 2,000 participants, including HCC patients, those with chronic liver diseases (hepatitis, cirrhosis, and benign liver space-occupying lesions), and healthy individuals. Blood samples from all participants will be divided into training and validation sets (1,400 and 600 cases, respectively) for the development and blind validation of the GAMAD (Gender + Age + Methylation + AFP + DCP) HCC-discriminating classifier. The classifier's accuracy and utility will be further assessed in the entire cohort (training and validation cohort). Primary outcome endpoints include sensitivity, specificity, and accuracy [ROC curves; area under the curve (AUC) value] of GAMAD for HCC (in early and each stage) and/or high-risk HCC groups. Secondary outcome endpoints involve comparing GAMAD with the established GALAD model and individual blood indices (AFP, DCP, and methylation testing) to evaluate: (1) GAMAD's clinical utility and significance for HCC patients in early and other stages (according to different staging systems: TNM staging, the Milan criteria, and the BCLC staging criteria); (2) GAMAD's discrimination ability for patients in various subgroups, including liver cirrhosis (LC) related HCC and LC, HBV related HCC and HBV, HCV related HCC and HCV, and nonalcoholic fatty liver disease (NAFLD) related HCC and NAFLD.
Clinical trial identification
NCT05626985.
Editorial acknowledgement
Legal entity responsible for the study
Eastern Hepatobiliary Surgery Hospital and The First Hospital of Jilin University.
Funding
Singlera Genomics Inc.
Disclosure
T. Yang: Financial Interests, Institutional, Principal Investigator: Eastern Hepatobiliary Surgery Hospital. H. Liu, H. Wang, S. Zhou, Z. Zheng, R. Liu: Financial Interests, Institutional, Full or part-time Employment: Singlera Genomics Inc. F. Shen: Financial Interests, Institutional, Principal Investigator: Eastern Hepatobiliary Surgery Hospital. G. Lv: Financial Interests, Institutional, Principal Investigator: First Hospital of Jilin University. All other authors have declared no conflicts of interest.
Resources from the same session
842P - Multicenter real-world study of newly diagnosed advanced-stage extranodal natural killer/T cell lymphoma (ENKTL): Proposal for intensive therapy
Presenter: Yu-Ce Wei
Session: Poster session 18
844P - Progression -free survival prediction of multiple myeloma patients in five European countries using machine learning models
Presenter: Maria Luisa Pleguezuelo Witte
Session: Poster session 18
845P - A machine learning based clinical platform for cancer subtyping and data integration in hematological malignancies
Presenter: Michelle Tang
Session: Poster session 18
846P - Artificial intelligence-driven identification of onco-hematology patients who may develop severe COVID-19
Presenter: Souad Assaad
Session: Poster session 18
847P - Fatal infections among leukemia patients
Presenter: Huijie Zhou
Session: Poster session 18
848P - Mortality after rasburicase vs allopurinol anti-hyperuricemia monotherapy in patients with liquid tumors
Presenter: Mitchell Cairo
Session: Poster session 18
849P - Long non-coding RNA signatures and their role in the progression of childhood T cell acute lymphoblastic leukemia
Presenter: Pankaj Sharma
Session: Poster session 18
850P - A zebrafish model of MYC-driven acute myeloid leukemia reveals that neutrophil resistance to oncogenic transformation depends on their ability to promote PP2A-mediated MYC proteasomal degradation
Presenter: Anna Maria Luciano
Session: Poster session 18
851P - Characterization of a zebrafish model of MYC-driven acute myeloid leukemia
Presenter: Anna Maria Luciano
Session: Poster session 18
852P - c-MAF-driven metabolic reprogramming mediates H3K27 hyperacetylation to regulate super enhancer-associated genes
Presenter: Phyllis SY Chong
Session: Poster session 18